Skip to main content
AVIR logo
AVIR
(NASDAQ)
Atea Pharmaceuticals, Inc.
$5.76-- (--)
Loading... - Market loading

Atea Pharmaceuticals (AVIR) Cash Flow Statement

Operating, investing, and financing activities with annual and quarterly data.

Atea Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Atea Pharmaceuticals, Inc. (AVIR) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-158.35-168.39-135.96-115.91121.19-10.95-14.03-9.06
Depreciation & Amortization0.420.420.420.260.030.020.020.02
Deferred Income Tax-6.360.00-48.560.00-29.390.00-0.500.00
Stock Based Compensation20.7251.7749.4346.7239.627.460.620.41
Change in Working Capital16.48-7.4816.16-46.59-247.85300.210.580.73
Change in Accounts Receivable0.000.000.000.000.00-5.820.000.00
Change in Accounts Payable8.490.211.70-1.9810.29-0.490.16-0.09
Change in Other Working Capital8.00-7.6814.46-44.60-258.13306.510.420.82
Other Operating Activities-4.94-11.8233.11-5.4729.390.000.500.54
Net Cash from Operating Activities-132.03-135.50-85.40-120.98-87.01296.73-12.81-7.91
Investing Activities
Capital Expenditures0.000.000.00-1.940.00-0.030.00-0.01
Acquisitions0.000.000.000.450.000.000.000.00
Purchases of Investments-281.9456.1140.30-545.350.000.000.000.00
Sales/Maturities of Investments470.73517.28602.6791.890.000.000.000.00
Other Investing Activities0.000.000.00-0.450.000.000.000.00
Net Cash from Investing Activities188.7956.1140.30-455.410.00-0.030.00-0.01
Financing Activities
Common Stock Issued0.060.270.260.231.47317.63-0.020.12
Common Stock Repurchased-25.520.000.000.000.000.000.000.00
Other Financing Activities-0.490.000.000.140.00214.120.0054.84
Net Cash from Financing Activities-25.750.270.260.371.47531.75-0.0227.48
Summary
Net Change in Cash31.02-79.13-44.84-576.02-85.54828.46-12.8319.56
Cash at Beginning of Period64.70143.82188.66764.68850.2221.7734.6015.04
Cash at End of Period95.7164.70143.82188.66764.68850.2221.7734.60
Free Cash Flow-132.03-135.50-85.40-122.93-87.01296.71-12.82-7.92

Frequently Asked Questions About Atea Pharmaceuticals Cash Flow

What is a cash flow statement?

A cash flow statement tracks the actual cash moving in and out of a company during a period. It's divided into three sections: operating activities (core business), investing activities (assets and investments), and financing activities (debt and equity). Unlike the income statement, it shows real cash rather than accounting profits.

What is operating cash flow?

Operating cash flow is the cash generated from a company's core business operations. It adjusts net income for non-cash items like depreciation and changes in working capital. Strong operating cash flow indicates the business can fund operations without external financing.

What is free cash flow (FCF)?

Free cash flow is operating cash flow minus capital expenditures. It represents the cash available for dividends, share buybacks, debt repayment, or reinvestment. FCF is considered one of the most important metrics for evaluating a company's financial health.

What are capital expenditures?

Capital expenditures (CapEx) are funds spent on acquiring or maintaining physical assets like property, equipment, and technology. CapEx appears in the investing activities section and is subtracted from operating cash flow to calculate free cash flow.

How is AVIR's cash generation trending?

Review Atea Pharmaceuticals's operating cash flow and free cash flow figures in the quarterly and annual data above. Consistent growth in operating cash flow relative to net income indicates high-quality earnings.

These financial metrics are calculated using cash flow data. Learn how each metric works and screen stocks by them.